Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure.
- Author:
Xiao-yun LIN
1
;
Li-zhong XIAO
;
Ling-jun GAO
;
Hong-fei ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adrenergic beta-Antagonists; therapeutic use; Adult; Aged; Aldosterone; blood; Angiotensin II; blood; Carbazoles; therapeutic use; Female; Heart Failure; blood; drug therapy; Humans; Magnesium; blood; Male; Middle Aged; Natriuretic Peptide, Brain; blood; Norepinephrine; blood; Propanolamines; therapeutic use
- From: Chinese Journal of Cardiology 2005;33(11):995-997
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure (CHF).
METHODSFifty-seven patients with CHF were divided into two groups randomly: received conventional treatment alone or combined with carvedilol for 8 weeks, respectively. Urine magnesium excretion (UME), plasma levels of magnesium (PMC), norepinephrine (NE), angiotensin-II (Ang-II), aldosterone (ALD), plasma renin activity (PRA) and peripheral monocyte magnesium content (MMC) were measured before and after treatments. Twenty-six health persons were selected as normal subjects.
RESULTSThere was a significant increase in UME and plasma concentrations of NE, ALD, Ang-II and PRA, and a significant decrease in MMC in patients with CHF, compared with the control group (P < 0.01). UME was positively correlated with ALD, Ang-II, PRA r = 0.41, 0.42, 0.38, respectively (P < 0.01). These parameters significantly improved after carvedilol (P < 0.05).
CONCLUSIONCarvedilol decreases significantly plasma concentrations of neurohormone and urine magnesium excretion, and increases cell magnesium content in patients with CHF.
